Publications

Haigh DB, Woodcock CL, Lothion-Roy J, Harris AE, Metzler VM, Persson JL, Robinson BD, Khani F, Alsaleem M, Ntekim A et al..  2022.  The METTL3 RNA Methyltransferase Regulates Transcriptional Networks in Prostate Cancer.. Cancers (Basel). 14(20)

Orfali N, O'Donovan TR, Cahill MR, Benjamin D, Nanus DM, McKenna SL, Gudas LJ, Mongan NP.  2020.  All-trans retinoic acid (ATRA)-induced TFEB expression is required for myeloid differentiation in acute promyelocytic leukemia (APL).. Eur J Haematol. 104(3):236-250.

Marcinkiewicz K, Scotland KB, Boorjian SA, Nilsson EM, Persson JLiao, Abrahamsson PAnders, Allegrucci C, Hughes IA, Gudas LJ, Mongan NP.  2012.  The androgen receptor and stem cell pathways in prostate and bladder cancers (review).. Int J Oncol. 40(1):5-12.

Boorjian S, Ugras S, Mongan NP, Gudas LJ, You X, Tickoo SK, Scherr DS.  2004.  Androgen receptor expression is inversely correlated with pathologic tumor stage in bladder cancer.. Urology. 64(2):383-8.

Quintero CM, Laursen KB, Mongan NP, Luo M, Gudas LJ.  2018.  CARM1 (PRMT4) Acts as a Transcriptional Coactivator during Retinoic Acid-Induced Embryonic Stem Cell Differentiation.. J Mol Biol. 430(21):4168-4182.

Hedblom A, Laursen KB, Miftakhova R, Sarwar M, Anagnostaki L, Bredberg A, Mongan NP, Gudas LJ, Persson JL.  2013.  CDK1 interacts with RARγ and plays an important role in treatment response of acute myeloid leukemia.. Cell Cycle. 12(8):1251-66.

Lothion-Roy J, Haigh DB, Harris AE, Metzler VM, Alsaleem M, Toss MS, Kariri Y, Ntekim A, Robinson BD, Khani F et al..  2022.  Clinical and molecular significance of the RNA m6A methyltransferase complex in prostate cancer.. Front Genet. 13:1096071.

Raman JD, Mongan NP, Liu L, Tickoo SK, Nanus DM, Scherr DS, Gudas LJ.  2006.  Decreased expression of the human stem cell marker, Rex-1 (zfp-42), in renal cell carcinoma.. Carcinogenesis. 27(3):499-507.

Mongan NP, Gudas LJ.  2007.  Diverse actions of retinoid receptors in cancer prevention and treatment.. Differentiation. 75(9):853-70.

Kauffman EC, Robinson BD, Downes M, Marcinkiewicz K, Vourganti S, Scherr DS, Gudas LJ, Mongan NP.  2013.  Estrogen receptor-β expression and pharmacological targeting in bladder cancer.. Oncol Rep. 30(1):131-8.

Harris AE, Metzler VM, Lothion-Roy J, Varun D, Woodcock CL, Haigh DB, Endeley C, Haque M, Toss MS, Alsaleem M et al..  2022.  Exploring anti-androgen therapies in hormone dependent prostate cancer and new therapeutic routes for castration resistant prostate cancer.. Front Endocrinol (Lausanne). 13:1006101.

Kopparapu PKumar, Boorjian SA, Robinson BD, Downes M, Gudas LJ, Mongan NP, Persson JL.  2013.  Expression of cyclin d1 and its association with disease characteristics in bladder cancer.. Anticancer Res. 33(12):5235-42.

Kopparapu PKumar, Boorjian SA, Robinson BD, Downes M, Gudas LJ, Mongan NP, Persson JL.  2013.  Expression of VEGF and its receptors VEGFR1/VEGFR2 is associated with invasiveness of bladder cancer.. Anticancer Res. 33(6):2381-90.

Raman JD, Mongan NP, Tickoo SK, Boorjian SA, Scherr DS, Gudas LJ.  2005.  Increased expression of the polycomb group gene, EZH2, in transitional cell carcinoma of the bladder.. Clin Cancer Res. 11(24 Pt 1):8570-6.

Orfali N, O'Donovan TR, Nyhan MJ, Britschgi A, Tschan MP, Cahill MR, Mongan NP, Gudas LJ, McKenna SL.  2015.  Induction of autophagy is a key component of all-trans-retinoic acid-induced differentiation in leukemia cells and a potential target for pharmacologic modulation.. Exp Hematol. 43(9):781-93.e2.

Orfali N, Shan-Krauer D, O'Donovan TR, Mongan NP, Gudas LJ, Cahill MR, Tschan MP, McKenna SL.  2019.  Inhibition of UBE2L6 attenuates ISGylation and impedes ATRA-induced differentiation of leukemic cells.. Mol Oncol.

Metzler VM, de Brot S, Haigh DB, Woodcock CL, Lothion-Roy J, Harris AE, Nilsson EM, Ntekim A, Persson JL, Robinson BD et al..  2023.  The KDM5B and KDM1A lysine demethylases cooperate in regulating androgen receptor expression and signalling in prostate cancer.. Front Cell Dev Biol. 11:1116424.

Orfali N, Jeyapalan JN, Woodcock CL, O'Donovan TR, Benjamin D, Cahill M, McKenna S, Gudas LJ, Mongan NP.  2019.  Lentiviral-Mediated shRNA Approaches: Applications in Cellular Differentiation and Autophagy.. Methods Mol Biol. 2019:33-49.

Kashyap V, Ahmad S, Nilsson EM, Helczynski L, Kenna S, Persson JLiao, Gudas LJ, Mongan NP.  2013.  The lysine specific demethylase-1 (LSD1/KDM1A) regulates VEGF-A expression in prostate cancer.. Mol Oncol. 7(3):555-66.

Nilsson EM, Laursen KB, Whitchurch J, McWilliam A, Ødum N, Persson JL, Heery DM, Gudas LJ, Mongan NP.  2015.  MiR137 is an androgen regulated repressor of an extended network of transcriptional coregulators.. Oncotarget. 6(34):35710-25.

Kubala JM, Laursen KB, Schreiner R, Williams RM, van der Mijn JC, Crowley MJ, Mongan NP, Nanus DM, Heller DA, Gudas LJ.  2023.  NDUFA4L2 reduces mitochondrial respiration resulting in defective lysosomal trafficking in clear cell renal cell carcinoma.. Cancer Biol Ther. 24(1):2170669.

Boorjian SA, Milowsky MI, Kaplan J, Albert M, Cobham MVallee, Coll DM, Mongan NP, Shelton G, Petrylak D, Gudas LJ et al..  2007.  Phase 1/2 clinical trial of interferon alpha2b and weekly liposome-encapsulated all-trans retinoic acid in patients with advanced renal cell carcinoma.. J Immunother. 30(6):655-62.

David KA, Mongan NP, Smith C, Gudas LJ, Nanus DM.  2010.  Phase I trial of ATRA-IV and Depakote in patients with advanced solid tumor malignancies.. Cancer Biol Ther. 9(9):678-84.

Laursen KB, Mongan NP, Zhuang Y, Ng MM, Benoit YD, Gudas LJ.  2013.  Polycomb recruitment attenuates retinoic acid-induced transcription of the bivalent NR2F1 gene.. Nucleic Acids Res. 41(13):6430-43.

Mongan NP, Martin KM, Gudas LJ.  2006.  The putative human stem cell marker, Rex-1 (Zfp42): structural classification and expression in normal human epithelial and carcinoma cell cultures.. Mol Carcinog. 45(12):887-900.